Fig. 3
SLC7A11 acts as a target of METTL3 depending on its m6A methyltransferase activity. A GO analysis of MeRIP-seq data. B and C Relative mRNA levels measured by RT-qPCR of selected genes in METTL3 knockdown H1975 and PC9 cells. D The relative abundance of m6A peaks of SLC7A11 mRNA in METTL3 knockdown and control PC9 cells analyzed by MeRIP-seq. E The protein levels showed by western blot of SLC7A11 with METTL3 knockdown in H1975 and PC9 cells. F and G The expression level of SLC7A11 mRNA and protein showed by RT-qPCR and western blot in METTL3 overexpression H322 cells. H Representative IHC images and IHC scores of SLC7A11 stained in xenograft tumors (Scale bar: 50 μm). I and J The m6A levels of SLC7A11 mRNA measured by MeRIP-qPCR analysis after METTL3 knockdown or METTL3 overexpression. K and L SLC7A11 mRNA half-lives (t1/2) showed by RNA decay rates followed by RT-qPCR after METTL3 knockdown in H1975 and PC9 cells and METTL3 overexpression in H322 cells. Data were collected at indicated timepoints (0 h, 3 h, and 6 h) with actinomycin D (Act D, 5 μg/mL) treatment. **P < 0.01, ***P < 0.001